Eli Lilly Lifts Revenue Forecast
Eli Lilly raised its full year revenue forecast after third quarter results beat expectations, driven by strong demand for its injectable weight loss drugs. The drugmaker also trimmed its profit outlook due to recent acquisition charges.
Xurve View
Insights:
Xurve View
Eli Lilly & Co raised its full-year revenue forecast to $91 billion following surging demand for its weight-loss treatments. The drugmaker topped third-quarter earnings expectations, driven by strong sales of its flagship obesity and diabetes injections. The results reinforce its market lead over Novo Nordisk A/S-B in the expanding GLP-1 sector.
